Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies

被引：41

作者：

Sharun, Khan ^{[1
]}

Tiwari, Ruchi ^{[2
]}

Dhama, Kuldeep ^{[3
]}

Emran, Talha Bin ^{[4
]}

Rabaan, Ali A. ^{[5
]}

Al Mutair, Abbas ^{[6
,7
,8
]}

机构：

[1] ICAR Indian Vet Res Inst, Div Surg, Bangalore, Uttar Pradesh, India

[2] Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu C, Coll Vet Sci, Dept Vet Microbiol & Immunol, Mathura, India

[3] ICAR Indian Vet Res Inst, Div Pathol, Bareilly, Uttar Pradesh, India

[4] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong, Bangladesh

[5] Johns Hopkins Aramco Hlthcare, Mol Diagnost Lab, Dhahran, Saudi Arabia

[6] Almoosa Specialist Hosp, Res Ctr, Alahsa, Saudi Arabia

[7] Prince Nora Univ, Coll Nursing, Riyadh, Saudi Arabia

[8] Wollongong Univ, Sch Nursing, Wollongong, NSW, Australia

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2021年 / 17卷 / 10期

关键词：

COVID-19; SARS-CoV-2; variants; neutralizing antibodies; vaccine efficacy; variant of concern;

D O I：

10.1080/21645515.2021.1923350

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been emerging and circulating in different parts of the world from the beginning of the coronavirus disease (COVID-19) pandemic. Variants are divided into three classes: variant of interest, variant of concern, and variant of high consequence depending on its impact on the transmission, disease severity, diagnostics, vaccines, and therapeutics. The variants of concern include the United Kingdom variant (B.1.1.7), South Africa variant (B.1.351), two related California variants (B.1.427 and B.1.429), and Brazil variant (P.1). These SARS-CoV-2 variants have a direct impact on the available COVID-19 vaccines and immunotherapeutics as they can alter the neutralizing activity of vaccine-elicited antibodies and monoclonal antibodies resulting in mild-to-substantial loss of efficacy. There is a need to establish surveillance systems that can monitor the emergence of novel SARS-CoV-2 variants worldwide.

引用

页码：3491 / 3494

页数：4

共 23 条

[1] Centre for Disease Control and Prevention, 2021, SARS COV 2 VARIANT C
[2] Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
Challen, Robert
Brooks-Pollock, Ellen
Read, Jonathan M.
Dyson, Louise
Tsaneva-Atanasova, Krasimira
Danon, Leon
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 372
[3] Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, Dami A.
De Marco, Anna
Ferreira, Isabella A. T. M.
Meng, Bo
Datir, Rawlings P.
Walls, Alexandra C.
Kemp, Steven A.
Bassi, Jessica
Pinto, Dora
Silacci-Fregni, Chiara
Bianchi, Siro
Tortorici, M. Alejandra
Bowen, John
Culap, Katja
Jaconi, Stefano
Cameroni, Elisabetta
Snell, Gyorgy
Pizzuto, Matteo S.
Pellanda, Alessandra Franzetti
Garzoni, Christian
Riva, Agostino
Elmer, Anne
Kingston, Nathalie
Graves, Barbara
Mccoy, Laura E.
Smith, Kenneth G. C.
Bradley, John R.
Temperton, Nigel
Ceron-Gutierrez, Lourdes
Barcenas-Morales, Gabriela
Harvey, William
Virgin, Herbert W.
Lanzavecchia, Antonio
Piccoli, Luca
Doffinger, Rainer
Wills, Mark
Veesler, David
Corti, Davide
Gupta, Ravindra K.
[J]. NATURE, 2021, 593 (7857) : 136 - +
[4] Covid-19: variants and vaccination
Darby, Alistair C.
Hiscox, Julian A.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 372
[5] Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, Nicholas G.
Abbott, Sam
Barnard, Rosanna C.
Jarvis, Christopher, I
Kucharski, Adam J.
Munday, James D.
Pearson, Carl A. B.
Russell, Timothy W.
Tully, Damien C.
Washburne, Alex D.
Wenseleers, Tom
Gimma, Amy
Waites, William
Wong, Kerry L. M.
van Zandvoort, Kevin
Silverman, Justin D.
Diaz-Ordaz, Karla
Keogh, Ruth
Eggo, Rosalind M.
Funk, Sebastian
Jit, Mark
Atkins, Katherine E.
Edmunds, W. John
[J]. SCIENCE, 2021, 372 (6538) : 149 - +
[6] Deng Xianding, 2021, medRxiv, DOI 10.1101/2021.03.07.21252647
[7] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Emary, Katherine R. W.
Golubchik, Tanya
Aley, Parvinder K.
Ariani, Cristina, V
Angus, Brian
Bibi, Sagida
Blane, Beth
Bonsall, David
Cicconi, Paola
Charlton, Sue
Clutterbuck, Elizabeth A.
Collins, Andrea M.
Cox, Tony
Darton, Thomas C.
Dold, Christina
Douglas, Alexander D.
Duncan, Christopher J. A.
Ewer, Katie J.
Flaxman, Amy L.
Faust, Saul N.
Ferreira, Daniela M.
Feng, Shuo
Finn, Adam
Folegatti, Pedro M.
Fuskova, Michelle
Galiza, Eva
Goodman, Anna L.
Green, Catherine M.
Green, Christopher A.
Greenland, Melanie
Hallis, Bassam
Heath, Paul T.
Hay, Jodie
Hill, Helen C.
Jenkin, Daniel
Kerridge, Simon
Lazarus, Rajeka
Libri, Vincenzo
Lillie, Patrick J.
Ludden, Catherine
Marchevsky, Natalie G.
Minassian, Angela M.
McGregor, Alastair C.
Mujadidi, Yama F.
Phillips, Daniel J.
Plested, Emma
Pollock, Katrina M.
Robinson, Hannah
Smith, Andrew
Song, Rinn
[J]. LANCET, 2021, 397 (10282) : 1351 - 1362
[8] Fischer R., 2021, BIORXIV, DOI 10.1101/2021.03.11.435000v2
[9] Francisco Martins A., 2021, MEDRXIV, DOI 10.1101/2021.03.09.21253204
[10] Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A.
Baillie, V
Cutland, C. L.
Voysey, M.
Koen, A. L.
Fairlie, L.
Padayachee, S. D.
Dheda, K.
Barnabas, S. L.
Bhorat, Q. E.
Briner, C.
Kwatra, G.
Ahmed, K.
Aley, P.
Bhikha, S.
Bhiman, J. N.
Bhorat, A' E.
du Plessis, J.
Esmail, A.
Groenewald, M.
Horne, E.
Hwa, S-H
Jose, A.
Lambe, T.
Laubscher, M.
Malahleha, M.
Masenya, M.
Masilela, M.
McKenzie, S.
Molapo, K.
Moultrie, A.
Oelofse, S.
Patel, F.
Pillay, S.
Rhead, S.
Rodel, H.
Rossouw, L.
Taoushanis, C.
Tegally, H.
Thombrayil, A.
van Eck, S.
Wibmer, C. K.
Durham, N. M.
Kelly, E. J.
Villafana, T. L.
Gilbert, S.
Pollard, A. J.
de Oliveira, T.
Moore, P. L.
Sigal, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (20) : 1885 - 1898

← 1 2 3 →